Search
Nitrendipine
go.drugbank.com/drugs/DB01054ApprovedWithdrawnIt is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. … Nitrendipine is a calcium channel blocker with marked vasodilator action.
Mixtures: ENEAS 10/20MG, ENEAS 10/20MGCategories: enalapril and nitrendipine, ACE Inhibitors and Calcium Channel BlockersDegarelix
go.drugbank.com/drugs/DB06699ApprovedInvestigationalDegarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. … Reduction in testosterone is important in treating men with advanced prostate cancer.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: Firmagon 120mg Powder and Solvent for Solution for Injection, Firmagon 80mg Powder and Solvent for Solution for InjectionBudesonide
go.drugbank.com/drugs/DB01222ApprovedInvestigationalBudesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. … [A188529,A188532] Budesonide was granted FDA approval on 14 February 1994.[L10598] It is also available in a combination product with [formoterol].[L10619]
Mixtures: Budesonide and Formoterol Fumarate Dihydrate, Budesonide and Formoterol Fumarate DihydrateCategories: Alimentary Tract and Metabolism, salbutamol and budesonideEvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies. … Evolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood.
Categories: Amino Acids, Peptides, and ProteinsProducts: REPATHA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 140MG/ML, Repatha Solution for Injection in Pre-filled Syringe 140mg/mL (evolocumab)The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxyglutaric aciduria
smpdb.ca/view/SMP0002358DiseaseThis results in modulations of HIF-mediated hypoxia responses and alterations in gene expression through global epigenetic remodelling that may contribute to malignant transformation. … The compound 2-hydroxyglutarate is the product of gain-of-function mutations producing mutIDH1 and mutIDH2 in the cytosolic and mitochondrial isoforms of isocitrate dehydrogenase (IDH).
Lercanidipine
go.drugbank.com/drugs/DB00528ApprovedInvestigationalWithdrawnLercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Mixtures: ZANIPRESS 20MG/10MG, ZANIPRESS 20MG/10MGCategories: Angiotensin II receptor blockers (ARBs) and calcium channel blockers, valsartan and lercanidipineVortioxetine
go.drugbank.com/drugs/DB09068ApprovedInvestigationalSome serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional … agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors.
Products: KELAC® 10MG, BRINTELLIX FILM-COATED TABLETS 10MGFluspirilene
go.drugbank.com/drugs/DB04842ApprovedWithdrawnA long-acting injectable antipsychotic agent used for chronic schizophrenia.
Products: Imap Forte Inj 10mg/ml, Imap Inj 2mg/mlItraconazole
go.drugbank.com/drugs/DB01167ApprovedInvestigational[L50051] Itraconazole was first approved in the US in 1992 [L50056] and is available orally. … While the intravenous formulation of the drug was formerly available, it was discontinued in the US in 2007.[A263232]
Categories: Triazole and tetrazole derivatives, Metabolic Side Effects of Drugs and SubstancesProducts: Itrafungol Oral Solution 10mg/ml, JAMP ITRACONAZOLE ORAL SOLUTION 10MG/MLEsketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigational[L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications … [L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.
Categories: Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsProducts: Eskelan 25 mg/ml-Injektions-/Infusionslösung in Ampullen, Eskelan 25 mg/ml-Injektionslösung in Durchstechflaschen